Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Venetoclax, and Obinutuzumab for CLL/SLL (NEXT STEP)
NCT04639362Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Dec 2020
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by HOVON. Started Dec 2020; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04639362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639362.